SynthesisTargeted oncology2026

CDK4/6 Inhibition in the Management of Metastatic HR+/HER2+ Breast Cancer: Systematic Review and Meta-analysis.

Daniel Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.